The use of cardiac remodeling agents such as angiotensin-converting enzyme (ACE) inhibitors or beta-blockers has not been fully studied in the pediatric population in the setting of persistent left ventricular systolic dysfunction (LVSD), and it is recommended that cancer survivors should have continued follow-ups with echocardiograms to monitor long-term effects of treatment [6]. This evidence concerns the gene ACE and cancer.